Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for luminal A breast cancer.
Introduction
Breast cancer is the most common malignant tumor in women worldwide (1) (2) (3) . Considering its wide morphological spectrum, clinical presentation and response to therapy, breast cancer is thought to be a highly heterogeneous malignancy. Cancer staging and establishment of molecular subtypes are important for physicians to develop treatment strategies (4) . In 2011, Original Article attendees of the 12th St. Gallen Consensus Meeting (5) suggested that breast cancer should be divided into four subtypes, luminal A type, luminal B type, human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancer. The use of these subtypes promoted the treatment of breast cancer from group therapy to classification therapy.
The American Joint Committee on Cancer (AJCC) cancer staging system is used by physicians and health care professionals worldwide to facilitate the uniform description and reporting of neoplastic diseases. The newest edition, the 8th edition of the AJCC cancer staging system (6) will be implemented on January 1st, 2018. Proper classification and staging of cancer is essential for physicians to administer proper treatment and evaluate the results of patient management and clinical trials. Classification and staging also serve as the standard for local, regional, and international reporting on the incidence and outcome of cancer.
In this retrospective study, we analyzed the clinical significance of the prognostic staging system of the 8th edition of AJCC cancer staging system for luminal A breast cancer. Follow-up data including 5-year disease free survival (DFS) and overall survival (OS) as well as other clinic-pathological data were collected to analyze the differences between the new prognostic staging subgroup and the traditional anatomic staging subgroup.
Materials and methods

Patient cohort
The study cohort comprised patients diagnosed with luminal A breast cancer and treated at the Breast Disease Center, Peking University First Hospital from January 2008 to December 2014. This study was approved by the Ethics Committee of Peking University First Hospital.
Molecular subtypes of breast cancer
The molecular subtypes evaluated in this study are based on the 2011 St. Gallen Consensus and are shown in Table 1 .
Histopathological grading and immunohistochemical examination of breast cancer
Each surgical specimen was immunohistochemically examined, and the results were assessed according to the American Society of Clinical Oncology/College of American Pathologists clinical practice guidelines (7, 8) .
Estrogen receptor (ER) and progesterone receptor (PR) positivity were defined as any level of nuclear positive (≥ 1%). HER2 positive was defined as immunohistochemical positivity (3+) or fluorescence in situ hybridization (FISH) overexpression. Ki67 positivity was defined in terms of its nuclear staining. The Ki67 labeling index was calculated as the percentage of MIB-1 positive cells among 1,000 malignant cells observed at high-power magnification (×400) (9) .
The histopathological grade was determined using the modified Scarff-Bloom-Richardson grading system (Nottingham Combined Histologic Grade) (10).
Anatomic and prognostic staging of breast cancer
Anatomic and prognostic staging was based on the 8th edition of AJCC cancer staging system (6) .
Statistical analysis
Survival data associated with different cancer stages and other clinicpathological data were analyzed with IBM SPSS Statistics (Version 19.0; IBM Corp., New York, USA). The DFS period was defined as the interval from the date of surgery to the date on which disease recurrence, either loco-regional or distant metastasis, was first observed, or the date of last follow-up without any evidence of recurrence. OS was calculated from the date of diagnosis of the primary breast cancer to the date of death or last follow-up. The Kaplan-Meier method was used to describe the DFS and OS and log-rank test was used to compare the differences between clinicpathological subgroups. The Breslow pairwise comparison was used to find the differences between any two subgroups of anatomic or prognostic stages in DFS and OS. P<0.05 (two-sided) was considered statistically significant.
Results
Patient characteristics
In Table 2 .
Differences between the 7th and 8th editions of AJCC cancer staging system for breast cancer
The anatomic staging system is identical between the 7th and 8th editions of AJCC cancer staging system for breast cancer. However, the prognostic staging system of breast cancer is totally new in the 8th edition. This prognostic staging system is characterized by the addition of several important biologic factors -grade, hormone receptor (ER, PR) expression, HER2 overexpression/amplification, and genomic panels [e.g., the Oncotype DX ® multigene panel, which produces a specific recurrence score (11, 12) Analysis by the log-rank test revealed statistically significant differences in 5-year DFS (P log-rank =0.003) between different disease stages, but no significant differences in 5-year OS (P log-rank =0.203). Analysis by the log-rank test showed statistically significant differences in both 5-year DFS (P log-rank =0.012) and 5-year OS (P logrank =0.006) between different prognostic stages. Table 3 and Figure 2 show the differences in DFS and OS in different stage groups among patients staged by the 8th edition of the AJCC prognostic staging system.
Pairwise comparisons of differences of DFS and OS between each sub-stage within anatomic and prognostic groups
The differences of 5-year DFS and OS between each substage within anatomic and prognostic groups are shown in Table 4 and Table 5 . There were statistic differences between anatomic stage I and II in 5-year DFS (P=0.001), but there were no statistic differences between each substage in 5-year OS. There were statistic differences between prognostic stage I, II and III in 5-year OS (P=0.000 and P=0.028), but no statistic differences between stage III and IV. There were no differences between each prognostic sub-stage in 5-year DFS.
Changes from anatomic stage groups to prognostic stage groups
Compared to the anatomic stage groups, the application of the prognostic staging system resulted in assignment of 175 of 421 (41.6%) patients to a different group. Most of them down-staged to better prognostic groups, only one patient with anatomic stage IIB cancer changed to prognostic stage IIIB. Figure 4 shows the DFS and OS analysis between the ana-III (pro-II) group and ana-III (pro-III) group.
Discussion
Four decades have passed since publication of the 1st edition of the AJCC staging manual in 1977. This staging system has become the most effective cancer classification and prognosis evaluation system worldwide. Cancers are classified into different stages depending on the TNM scoring system: tumor size, lymph nodes affected, and metastases. The 7th edition of the AJCC cancer staging system published in 2010 is still based on clinic- pathological information (13). The 8th edition of the AJCC breast cancer anatomic staging is also based on the TNM system, however, the evolving knowledge of breast cancer biology and the increased validation of various biomarkers including genomic profiling have made the anatomic staging alone less sufficient to show the differences in the molecular characteristics of breast cancer (14,15). Breast cancers with different molecular characteristics have different prognoses, patterns of recurrence, and dissimilarities of sensitivities to systemic therapies (16) . Thus, the most substantial change in the 8th edition of the AJCC staging system is its brand-new prognostic staging system, and this is the biggest highlight of the revision of this edition, the Breast Cancer Expert Panel recommends prioritizing the use of this prognostic staging system in patients with breast cancer.
Taken into consideration of its heterogeneity, breast cancer has different response to therapy and prognoses between each subtype (17) . Because of ER and PR positive, HER2 negative, low ki67 expression, and often low Oncotype DX ® recurrence score (18) , luminal A breast cancer is associated with better DFS and OS than other molecular subtypes (19) . In order to study the differences between the 8th edition of the AJCC anatomic staging system and prognostic staging system for breast cancer, we retrospectively classified 421 patients with luminal A breast cancer treated in the Breast Disease Center, Peking University First Hospital using both the anatomic and prognostic staging systems. The overall 5-year DFS and OS rates were 98.3% and 99.3%, respectively. In the anatomic stage groups, we observed significant statistic differences in 5-year DFS (log-rank=11.933, P=0.003) between different disease stages, but no significant statistic differences in 5-year OS (log-rank=4.606, P=0.203). In the prognostic stage groups, we observed significant statistic differences in both 5-year DFS (log-rank=8.816, P=0.012) and 5-year OS (log-rank=12.581, P=0.006) between different prognostic stages. This might be a proof that the prognostic stage can predict the OS better than the anatomic stage, even in patients with luminal A breast cancer, which had a very high 5-year OS of 99.3% in the present study. By adding important biologic factors [grade, hormone receptor (ER, PR) expression, HER2 overexpression/ amplification and genomic panels] to the anatomic TNM staging system, the 8th edition of the AJCC prognostic staging system has caused some patients' disease stages to Considering the differences in pathological characteristics, risk of relapse, and sensitivities to available therapies among individual patients with breast cancer, cancer staging is so important that it should not only provide information on the biological features of the breast cancer, but also reflect the molecular characteristics of the breast cancer. A personalized-medicine approach to breast cancer also requires more precise cancer staging and molecular profiling of breast cancer (20, 21) . Based on all the currently available knowledge including both the biological and molecular characteristics of breast cancer (22) (23) (24) , the evidence-based anatomic TNM staging system is supplemented, as appropriate, by selected molecular markers and newly acquired insights into the molecular underpinnings of cancer, the 8th edition of the AJCC cancer staging system has developed prognostic staging system, which serves as a bridge from a population-based to a more personalized approach to cancer staging (25) . In the present study, more than 40% of patients with luminal A breast cancer were down-staged to better prognostic cancer stages than their anatomic stages. With these adjustments of cancer stages, patients with breast cancer might have the opportunity to avoid excessive treatment without affecting their prognosis.
This was a single-center retrospective study with a relatively small number of patients. More multi-center prospective studies should be performed to more fully determine the clinical value of the prognostic staging system in patients with breast cancer. We believe that prognostic staging system will become another gold standard cancer classification system along with the anatomic staging system or an even more effective system as a guide to select whether to apply systemic therapy in patients with breast cancer.
Conclusions
The 8th edition of the AJCC prognostic staging system is an important supplement to the current breast cancer staging system. More clinical trials are needed to prove its significance in guiding the selection of proper systemic therapy and predicting the prognosis of breast cancer.
